Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication DATSCAN is indicated as an adjunct to other diagnostic evaluations for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging in adult patients with: suspected Parkinsonian syndromes (PS) or suspected dementia with Lewy bodies (DLB). FDA label
DatSCAN · 1 trial · 4 indications
| Name | Type | Description |
|---|---|---|
| DatSCAN | DRUG | - |
Inclusion Criteria: * Subjects must be adults between 55 to 90 years of age with an established diagnosis for dementia in accordance with DSM-IV criteria and have to fulfil at least one of the following: The ICC criteria for probable and possible DLB, the National Institute of Neurological and Comm...
DatSCAN is an investigational small molecule being studied for use in Lewy Body Dementia. It is a dopamine transporter scintigraphy imaging agent, also known as DAT-imaging, intended to help in the evaluation of patients with this condition. The drug is currently in Phase 3 clinical development.
DatSCAN targets the dopamine transporter, a protein involved in the reuptake of dopamine in the brain. By binding to this transporter, DatSCAN enables visualization of dopamine nerve terminals through scintigraphy imaging, which may aid in the assessment of Lewy Body Dementia.
DatSCAN is being developed by GE HealthCare Technologies Inc., a company publicly traded under the ticker GEHC. The company is conducting clinical research to evaluate the drug's potential in the field of neurology, specifically for Lewy Body Dementia.
DatSCAN is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial for DatSCAN has been completed, and the drug remains under evaluation for its intended use in Lewy Body Dementia.
DatSCAN has one completed Phase 3 clinical trial registered under NCT00209456, titled "Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia." This trial enrolled 326 participants in Germany, including patients with Lewy Body Dementia, non-DLB dementia, Alzheimer's, and vascular dementia.
DatSCAN is associated with dopamine transporter scintigraphy imaging, often referred to as DAT-imaging. The clinical trial for DatSCAN specifically uses this imaging technique to evaluate patients with Lewy Body Dementia. The drug itself is the imaging agent used in this diagnostic procedure.